StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$78.94−5.84 (-6.89%)

Close on Nov 17, 2026Market cap $7.00BP/E –Yield –

CG Oncology cash

Cash and short-term investments held at the end of each period.

CG Oncology's cash was $984.46M at Sep 30, 2026. For fiscal 2025 it was $742.16M, up 0.0% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$742.16M+0.0%
FY2024Dec 31, 2024$742.00M+295.4%
FY2023Dec 31, 2023$187.67M+112.9%
FY2022Dec 31, 2022$88.14M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$984.46M+44.7%
Q2 FY2026Jun 30, 2026$1.03B+55.6%
Q1 FY2026Mar 31, 2026$1.08B+56.3%
Q4 FY2025Dec 31, 2025$742.16M+0.0%
Q3 FY2025Sep 30, 2025$680.26M+25.8%
Q2 FY2025Jun 30, 2025$661.05M+19.6%
Q1 FY2025Mar 31, 2025$688.43M+21.5%
Q4 FY2024Dec 31, 2024$742.00M+295.4%
Q3 FY2024Sep 30, 2024$540.71M+5163.4%
Q2 FY2024Jun 30, 2024$552.88M+608.5%
Q1 FY2024Mar 31, 2024$566.51M+81647.2%
Q4 FY2023Dec 31, 2023$187.67M+112.9%
Q3 FY2023Sep 30, 2023$10.27M–
Q2 FY2023Jun 30, 2023$78.04M–
Q1 FY2023Mar 31, 2023$693.00K–
Q4 FY2022Dec 31, 2022$88.14M–

More CG Oncology figures

See a number that looks wrong?